These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 9798693)

  • 21. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
    J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Early diagnosis and comprehensive treatments of post-transplantation lymphoproliferative disorder after pediatric liver transplantation].
    Deng Z; Jiang L; Zhou T; Shen C; Chen Q; Xia Q
    Zhonghua Er Ke Za Zhi; 2014 Aug; 52(8):579-82. PubMed ID: 25224233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy.
    Barış Z; Özçay F; Yılmaz Özbek Ö; Haberal N; Sarıalioğlu F; Haberal M
    Turk J Gastroenterol; 2018 May; 29(3):354-360. PubMed ID: 29755021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Various initial presentations of Epstein-Barr virus infection-associated post-transplant lymphoproliferative disorder in pediatric liver transplantation recipients: Case series and literature review.
    Simakachorn L; Tanpowpong P; Lertudomphonwanit C; Anurathapan U; Pakakasama S; Hongeng S; Treepongkaruna S; Phuapradit P
    Pediatr Transplant; 2019 Mar; 23(2):e13357. PubMed ID: 30661283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation.
    Gridelli B; Spada M; Riva S; Colledan M; Segalin A; Lucianetti A; Sonzogni A; Furione M; Baldanti F; Torre G
    Transpl Int; 2000; 13 Suppl 1():S399-401. PubMed ID: 11112041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience.
    Pinho-Apezzato ML; Tannuri U; Tannuri AC; Mello ES; Lima F; Gibelli NE; Santos MM; Ayoub AA; Maksoud-Filho JG; Velhote MC; Silva MM; Andrade WC; Miyatani HT
    Transplant Proc; 2010 Jun; 42(5):1763-8. PubMed ID: 20620519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus infection after pediatric living-related liver transplantation--management and risk factors.
    Shigeta T; Imadome K; Sakamoto S; Fukuda A; Kakiuchi T; Matsuno N; Tanaka H; Nakazawa A; Kasahara M
    Transplant Proc; 2010 Dec; 42(10):4178-80. PubMed ID: 21168657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
    Newell KA; Alonso EM; Kelly SM; Rubin CM; Thistlethwaite JR; Whitington PF
    J Pediatr; 1997 Jul; 131(1 Pt 1):98-104. PubMed ID: 9255199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy.
    Kullberg-Lindh C; Saalman R; Olausson M; Herlenius G; Lindh M
    Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28039929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
    Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
    Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of immunosuppression on the development of Epstein-Barr virus (EBV) viremia after pediatric liver transplantation.
    Lu BR; Park KT; Hurwitz M; Cox KL; Berquist WE
    Transplant Proc; 2013; 45(1):301-4. PubMed ID: 23267800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric Gastrointestinal Posttransplant Lymphoproliferative Disorder: Incidence, Clinical Characteristics, and Impact of Major Surgical Interventions Upon Overall Survival.
    Dziegielewski C; Contreras R; Weitzman S; Gerstle JT
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):438-444. PubMed ID: 29794643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
    Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M
    Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.
    Offor UT; Bacon CM; Roberts J; Powell J; Brodlie M; Wood K; Windebank KP; Flett J; Hewitt T; Rand V; Hasan A; Parry G; Gennery AR; Reinhardt Z; Bomken S
    J Heart Lung Transplant; 2021 Jan; 40(1):24-32. PubMed ID: 33339556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.